Immunic Says Open-Label Extension Data Support Durability Of Vidofludimus Calcium Disability Outcomes In Phase 2 Progressive MS Trial
Share
Why It Matters
Immunic's MS medicine showed it kept helping patients longer than expected. When a medicine keeps working over time, it hints the company might have something worth developing.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.